Skip to main content

Advertisement

SpringerLink
Log in

The role of fibrin in tumor metastasis

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

A volume of data that has accumulated for over a century has suggested that fibrin may facilitate the persistence and progression of malignancy. Techniques that have been developed recently have shown that fibrin is indeed a component of the connective tissue stroma in human malignancy but in only a few tumor types. However, therapeutic intervention studies with drugs that limit thrombin activity or enhance fibrinolysis have shown favorable clinical effects in at least one such tumor type. These favorable findings affirm the concept that cause-and-effect relationships do, in fact, exist between thrombin generation with fibrin formation and tumor progression, and suggest that a rational basis exists for the design of future drug intervention trials that target reactions relevant to specific tumor types. These findings also provide a basis for the design of experiments capable of defining further the role of fibrin in the integrity of these tumor types. Because fibrinogen is found much more commonly than fibrin in the connective tissue of a variety of human malignancies, attention might reassumably be directed to determining the possible contribution of this molecule as well as of fibrin to tumor progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. ZacharskiLR: Anticoagulation in the treatment of cancer in man. In: DonatiMB, DavidsonJ, GarattiniS (ed) Malignancy and the hemostatic system. Raven Press, New York, pp 113–128, 1981

    Google Scholar 

  2. RicklesFR, EdwardsRL: Activation of blood coagulation in patients with cancer: Trousseau's syndrome revisited. Blood 62: 14–31, 1983

    PubMed  Google Scholar 

  3. DonatiMB, PoggiA, SemeraroN: Coagulation and malignancy. In: PollerL (ed) Recent advances in blood coagulation. Livingston, New York, pp 375–391, 1981

    Google Scholar 

  4. ZacharskiLR, HendersonWG, RicklesFR, FormanWG, CornellCJ, HarrowerHW, JohnsonRO: Rationale and experimental design for the VA Cooperative study of anticoagulation (warfarin) in the treatment of cancer. Cancer 44: 732–741, 1979

    PubMed  Google Scholar 

  5. RicklesFR, HancockWW, EdwardsRL, ZacharskiLR: Antimetastatic agents. I. The role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Sem Thrombos Hemostas 14: 88–94, 1988

    Google Scholar 

  6. DvorakHF: Tumors: Wounds that do not heal. New Engl J Med 315: 1650–1659, 1986

    PubMed  Google Scholar 

  7. DvorakHF: Thrombosis and cancer. Human Pathol 18: 275–284, 1987

    Google Scholar 

  8. DvorakHF, HarveyVS, BuchinskiB, EstrellaP, McDonaghJ, DvorakAM: Fibrin gels induce angiogenesis: a new assay with implications for tumor stroma generation and wound healing. Fed Proc 46: 970, 1987

    Google Scholar 

  9. BrownLF, AschB, HarveyVS, BuchinskiB, DvorakHF: Fibrinogen influx and accumulations of cross-linked fibrin in mouse carcinomas. Cancer Res 48: 1920–1925, 1988

    PubMed  Google Scholar 

  10. DvorakHF, SengerDR, DvorakAM: Fibrin as a componant of the tumor stroma: origins and biological significance. Cancer Metast Rev 2: 41–73, 1983

    Google Scholar 

  11. ZacharskiLR, MemoliVA, CostantiniV, WojtukiewiczMZ, OrnsteinDL: Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coag Fibrinolys 1: 71–78, 1990

    Google Scholar 

  12. ZacharskiLR, HowellAL, MemoliVA: The coagulation biology of cancer. Fibrinolysis 6 (Suppl): 39–42, 1992

    Google Scholar 

  13. CardinaliM, UchinoR, ChungSI: Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lumpholkine-activated killer cells. Cancer Res 50: 8010–8016, 1990

    PubMed  Google Scholar 

  14. GunjiY, GorelikE: Role of fibrin coagulation in protection of murine tumor cells from destruction by immune cells. Cancer Res 48: 5216–5221, 1988

    PubMed  Google Scholar 

  15. ZacharskiLR, HendersonWG, RicklesFR, FormanWG, VanEeckhoutJP, CornellCJ, ForcierRJ, MartinJF: Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Am J Clin Oncol 5: 593–609, 1982

    PubMed  Google Scholar 

  16. KarpatkinS, PearlsteinE: Role of platelets in tumor cell metastasis. Ann Int Med 95: 636–641, 1981

    PubMed  Google Scholar 

  17. ZacharskiLR, HendersonWG, RicklesFR, FormanWB, CornellCJ, ForcierRJ, HeadleyE, KimS-H: Effect of sodium warfarin on survival in small cell carcinoma of the lung. J Am Med Assoc 245: 831–835, 1981

    Google Scholar 

  18. ZacharskiLR, HendersonWG, RicklesFR, FormanWB, CornellCJ, ForcierRJ, EdwardsRL, HeadleyE: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA Cooperative Study 75. Cancer 53: 2046–2052, 1984

    PubMed  Google Scholar 

  19. ChahinianAP, PropertKJ, WareJH, ZimmerB, PerryMC, HirshV, SkarinA, KopelS: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7: 993–1002, 1989

    PubMed  Google Scholar 

  20. CalvoPA, HarguindeySS, AparicioLA, DyC, GilA, RochaE: Urokinase and combination chemotherapy for treatment of small cell carcinoma of the lung. Cancer Treat Sympos 2: 105–108, 1985

    Google Scholar 

  21. CalvoFA, SantosM, HidalgoOF: Urokinase-combination chemotherapy in small cell lung cancer: A phase II study. Proc ASCO 9: 237, 1991

    Google Scholar 

  22. LebeauB, ChastangCL, BrechotJM: Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 7 (Suppl): 129, 1991

    Google Scholar 

  23. DonatiMB, DavidsonJF, GarattiniS: Malignancy and the hemostatic system. Raven Press, N.Y., 1981

    Google Scholar 

  24. SalsaliM, ClifftonEE: Superior vena caval obstruction with lung cancer. Ann Thoracic Surg 6: 437–442, 1968

    Google Scholar 

  25. AstedtB, GlifbergI, MattssonW, TropeC: Arrest of growth of ovarian tumor by tranexamic acid. J Am Med Assn 238: 154–155, 1977

    Google Scholar 

  26. KudrykB, RohozaA, AhadiM, ChinJ, WiebeME: Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 21: 89–94, 1984

    PubMed  Google Scholar 

  27. KudrykB, GrossmanZD, McAfeeJG, RosebroughSF: Monoclonal antibodies as probes for fibrin(ogen) proteolysis. In: ChatalJF (ed) CRC Press, Boca Raton, Florida, pp 365–398, 1989

    Google Scholar 

  28. ZacharskiLR, MemoliVA, RousseauSM, KisielW: Coagulation-cancer interactionin situ in small cell carcinoma of the lung. Cancer 60: 2675–2681, 1987

    PubMed  Google Scholar 

  29. ZacharskiLR, MemoliVA, RousseauSM: Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung. Cancer 62: 299–302, 1988

    PubMed  Google Scholar 

  30. WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65: 481–485, 1990

    PubMed  Google Scholar 

  31. ZacharskiLR, MemoliVA, RousseauSM: Cancer-coagulation interactionin situ in renal cell carcinoma. Blood 68: 394–399, 1986

    PubMed  Google Scholar 

  32. WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Fibrinogen-fibrin transformationin situ in renal cell carcinoma. Anticancer Res 10: 579–582, 1990

    PubMed  Google Scholar 

  33. WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RouseauSA, StumpDC: Malignant melanoma: Interaction with coagulation and fibrinolysis pathwaysin situ. Am J Clin Pathol 93: 516–521, 1990

    PubMed  Google Scholar 

  34. OrnsteinD, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, HuntJ, RousseauSM, StumpDC: Coexistant macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 68: 1061–67, 1991

    PubMed  Google Scholar 

  35. CostantiniV, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, HuntJ, RousseauSM, StumpDC: Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 51: 349–353, 1991

    PubMed  Google Scholar 

  36. CostantiniV, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, HuntJ, RousseauSM, StumpDC: Occurence of components of fibrinolysis pathwaysin situ in neoplastic and non-neoplastic human breast tissue. Cancer Res 51: 354–358, 1991

    PubMed  Google Scholar 

  37. WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Indirect activation of blood coagulation in colon cancer. Thrombosis and Haemostasis 62: 1062–1066, 1989

    PubMed  Google Scholar 

  38. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Moritz TE, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC: Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 67: 1991

  39. WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Absence of components of coagulation and fibrinolysis pathwaysin situ in mesothelioma. Thrombos Res 55: 279–284, 1989

    Google Scholar 

  40. CostantiniV, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue. J Lab Clin Med 119: 124–131, 1992

    PubMed  Google Scholar 

  41. ZacharskiLR, DunwiddieC, NuttEM, HuntJ, MemoliVA: Cellular localization of activated factor X by a Xa-specific probe. Thromb Haemost 65: 545–548, 1991

    PubMed  Google Scholar 

  42. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM: Distribution of tissue factor pathway inhibitor (TFPI, EPI, LACI) in normal and pathologic human tissues. Blood 78: 72a, 1991

  43. ZacharskiLR, DunwiddieC, NuttEM, HuntJ, MemoliVA: Cellular localization of activated factor X by a Xa-specific probe. Thromb Haemost 65: 545–548, 1991

    PubMed  Google Scholar 

  44. FingertHJ, ChenZ, MigrakiN, GajewakiWH, BambergMP, KradinRL: Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay. Cancer Res 47: 3824–3829, 1987

    PubMed  Google Scholar 

  45. BogdenAE, CobbWR, LepageDJ, HaskellPM, GulkinTA, WardA, KeltonDE, EsberHJ: Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six day subrenal capsule assay. Cancer 48: 10–20, 1981

    PubMed  Google Scholar 

  46. OlanderJV, BremerME, MarasaJC, FederJ: Fibrin-enhanced endothelial cell organization. J Cell Physiol 125: 1–9, 1985

    PubMed  Google Scholar 

  47. BlombackB, OkadaM, ForslindB, LarssonU: Fibrin gels as biological filters and interfaces. Biorheology 21: 93–104, 1984

    PubMed  Google Scholar 

  48. ColvinRB, GardnerPI, RoblinRO, VerderberEL, LaniganJM, MosessonMW: Cell surface fibrinogen-fibrin receptors on cultured human fibroblasts. Lab Invest 41: 464–473, 1979

    PubMed  Google Scholar 

  49. AzzaroneB, Frouty-BoyeD, Macieira-CoelhoA: Relationship between fibrin clot retraction and tumorigenesis in C3H/1071/2 cells. Int J Cancer 28: 799–803, 1981

    PubMed  Google Scholar 

  50. CuratoloL, AzzaroneB, Fally-CrepinC, MorascaL, Macieira-CoelhoA: Comparison of fibrin clot retraction with other transformation parameters after hybridization of normal and established cell lines. Int J Cancer 31: 249–255, 1983

    PubMed  Google Scholar 

  51. HopperKE, GeczyCL, DaviesWA: A mechanism of migration inhibition in delayed-type hypersensitivity reactions. I Fibrin deposition on the surface of elicited peritoneal macrophagesin vivo. J Immunol 126: 1052–7, 1981

    PubMed  Google Scholar 

  52. SultanAM, DunnCJ, WilloughbyDA: Leukocyte migration inhibition activity of nonimmune acute inflammatory pleural exudate. Inflammation 3: 305–317, 1979

    PubMed  Google Scholar 

  53. CianoPS, ColvinRB, DvorakAM, McDonaghJ, DvorakHF: Macrophage migration in fibrin gel matrices. Lab Invest 54: 62–70, 1986

    PubMed  Google Scholar 

  54. ChereshDA, SmithJW, CooperHM, QuarantaV: A novel vitronectin receptor integrin (alpha V beta X) is responsible for distinct adhesive properties of carcinoma cells. Cell 57: 59–69, 1989

    PubMed  Google Scholar 

  55. ChereshDA, SiroRC: Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronection, fibrinogen, and von Willebrand factor. J Biol Chem 262: 17703–17711, 1987

    PubMed  Google Scholar 

  56. YlanneJ, HormiaM, JarvinenM, VartioT, VirtanenI: Platelet glycoprotein IIG IIIa complex in cultured cells. Localization in focal adhesion sites in spreading HEL cells. Blood 72: 1478–1486, 1988

    PubMed  Google Scholar 

  57. SosmanJA, KohlerPC, HankJ, MooreKH, BechhoferR, StorerB, SondelPM: Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60–63, 1988

    PubMed  Google Scholar 

  58. WestWH, TauerKW, YannelliJR, MarshallGD, OrrDW, ThurmenGB, OldhamRK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905, 1987

    PubMed  Google Scholar 

  59. GreenbergCS, BirckbichlerPJ, RiceRH: Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5: 3071–7, 1991

    PubMed  Google Scholar 

  60. MurthySNP, LorandL: Cross-linked Ax.8 chain hybrids serve as unique markers for fibrinogen polymerized by tissue transglutaminase. Proc Natl Acad Sci 87: 9679–9682, 1990

    PubMed  Google Scholar 

  61. AlaouiSE, LegasteloisS, RochAM, ChantepieJ, QuashG: Transglutaminase activity and NE (γ-glutamyl) lysine isopeptide levels during cell growth: an enzymic and immunological study. Int J Cancer 48: 221–226, 1991

    PubMed  Google Scholar 

  62. RochAM, DuchetM, LointierP, QuashG: Polyamine biosynthesis, degradation and sequestration in tumors, polyps and histologically normal mucosa from the human colon. In: PerinA, ScalabrinoG, SessaA, FerioliME (ed) Perspectives in polyamine research. Wichtig, Milan, 129–132, 1988

    Google Scholar 

  63. ReidMB, GrayC, FearJD, BirdCC: Immunohistological demonstration of factors XIIIa and XIIIs in reactive and neoplastic fibroblastic and fibrohistiocytic lesions. Histopathol 10: 1171–1178, 1986

    Google Scholar 

  64. RochAM, NoelP, AlaoiniSE, CharlotC, QuashG: Differential expression of isopeptide bonds NE (γ-glutamyl) lysine in benign and malignant human breast lesions: an immunohistochemical study. Int J Cancer 48: 215–220, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Internal and Vascular Medicine, Università of Perugia, Perugia, Italy

    Vincenzo Costantini

  2. The Department of Medicine, Dartmouth Medical School, 05009, White River Junction, Vermont, USA

    Leo R. Zacharski

  3. the Department of Veterans Affairs Medical Center, 05009, White River Junction, Vermont, USA

    Vincenzo Costantini

Authors
  1. Vincenzo Costantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leo R. Zacharski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costantini, V., Zacharski, L.R. The role of fibrin in tumor metastasis. Cancer Metast Rev 11, 283–290 (1992). https://doi.org/10.1007/BF01307183

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01307183

Key words

Search

Navigation